 |
|
 |
 | |
|
|
- Non-Hodgkin lymphoma (NHL) is one of the fastest rising cancers in the United States (Source: National Cancer Institute SEER Cancer Statistics Review). The age-adjusted incidence of NHL rose by 79 percent from 1975 to 2005, an average annual percentage increase of 2.6 percent (Source: The Leukemia & Lymphoma Society).
- NHL is the sixth most common cancer among males and the fifth most common cancer among females (Source: Melissa Conrad Stöppler, MD and William C. Shiel Jr., MD, FACP, FACR, MedicineNet.com).
- NHL accounts for about 6 percent of childhood cancers (Source: Nemours Foundation, Jacksonville, FL ).
- About 66,120 people living in the United States will be diagnosed with non-Hodgkin lymphoma (NHL) in 2008 (Source: The Leukemia & Lymphoma Society).
- From 2001-2005, the median age at diagnosis was 67 years of age and the median age at death was 75 years of age for NHL (Source: National Cancer Institute SEER Cancer Statistics Review).
- Based on rates from 2003-2005, 2.05% of men and women born today will be diagnosed with NHL at some time during their lifetime (Source: National Cancer Institute SEER Cancer Statistics Review).
- NHL disproportionately affects males. Among the new cases of NHL in 2008, 35,450 will be males and 30,670 females (Source: The Leukemia & Lymphoma Society).
- Although blacks, starting in their mid-to-late teens to mid-50s, have higher incidence rates of NHL than whites, whites, beginning at age 60, generally have much higher incidence rates than blacks (Source: The Leukemia & Lymphoma Society).
- At least 3,000 of the non-Hodgkin lymphomas each year were associated with AIDS (Source: National Cancer Institute).
- NHL is comprised of different subtypes grouped into low grade, intermediate grade, and high grade lymphomas.
- Survival rates vary widely based on the type of lymphoma and stage of disease at the time of diagnosis. However, according to the American Cancer Society, the overall 5-year relative survival rate for people with non-Hodgkin lymphoma is 63% (though the National Cancer Institute puts it at closer to 67 percent), and 10-year relative survival is 51%.
|
| |
|
